Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centre for Mendelian Genomics, |
RCV000415151 | SCV000492722 | pathogenic | Developmental delay; dystrophia | 2014-06-06 | criteria provided, single submitter | clinical testing | |
Centre for Mendelian Genomics, |
RCV000414833 | SCV000493027 | pathogenic | Hypertrichosis; Global developmental delay; Feeding difficulties; Abnormal corpus callosum morphology; Delayed speech and language development; Glabellar hemangioma; Small for gestational age; Delayed gross motor development; Prominent metopic ridge; Intellectual disability, severe | 2014-06-06 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000627196 | SCV000748180 | pathogenic | not provided | 2022-03-02 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 31974359, 25525159, 21706002, 28229513, 25590979, 34527642) |
Hudson |
RCV000023977 | SCV000992552 | pathogenic | Bohring-Opitz syndrome | 2019-04-05 | criteria provided, single submitter | research | ACMG codes: PVS1, PSM4, PP4, PP5 |
Centre for Mendelian Genomics, |
RCV001199371 | SCV001370470 | pathogenic | Myelodysplastic syndrome | 2016-01-01 | criteria provided, single submitter | clinical testing | This variant was classified as: Pathogenic. |
Duke University Health System Sequencing Clinic, |
RCV000023977 | SCV003919071 | pathogenic | Bohring-Opitz syndrome | 2023-04-20 | criteria provided, single submitter | research | |
OMIM | RCV000023977 | SCV000045268 | pathogenic | Bohring-Opitz syndrome | 2011-06-26 | no assertion criteria provided | literature only |